This market resolves to Yes if the U.S. Food and Drug Administration (FDA) approves a new therapy for pancreatic cancer, specifically one targeting the mutated gene responsible for 90% of cases, by December 31, 2027. The therapy must be based on the recent breakthrough described in news where mice trials showed significant tumor regression without side effects.